Krueger G G, Morgan J R, Jorgensen C M, Schmidt L, Li H L, Kwan M K, Boyce S T, Wiley H S, Kaplan J, Petersen M J
Department of Medicine, University of Utah Health Services Center, Salt Lake City 84132.
J Invest Dermatol. 1994 Nov;103(5 Suppl):76S-84S. doi: 10.1111/1523-1747.ep12399100.
Molecular definition of disease at the level of the gene and advances in recombinant DNA technology suggest that many diseases are amenable to correction by genes not bearing the defective elements that result in disease. Many questions must be answered before this therapy can be used to correct chronic diseases. These questions fall into safety and efficacy categories. Experience with transplanting cellular elements of skin or skin substitutes (defined as skin that possess the cell types and a dermal structure to develop into a functioning skin) to athymic rodents is considerable and is seen as a system where these questions can be answered. This paper reviews these questions and presents our early analysis of genetically modified cells in skin substitutes in vivo and in vitro. Experimental data demonstrate that both a matrix of woven nylon, housing a fibroblast generated collage, and dead dermis can be utilized to shuttle genetically modified human fibroblasts from the laboratory to an in vivo setting. Genetically modified fibroblasts do not migrate from the shuttle to the surrounding tissue. The survival of significant numbers, approximately 70%, of genetically modified fibroblasts for at least 6 weeks in these shuttles, supports this general approach as having clinical utility. It is also concluded that skin substitute systems can be used to generate a genetically modified skin in vitro that has the capacity to develop into functional skin in vivo. Further, as genetically modified keratinocytes differentiate there is increased production by the transgene, supporting the concept that keratinocytes have true potential as shuttles for therapeutic genes. This work demonstrates that transplantation of systems containing genetically modified cells of the skin can be used to experimentally define many aspects of gene therapy using skin before this technology is taken to the clinic. Examples include determining the effect of gene transduction and expression on structure and function of the genetically modified skin as well as on distant skin and an assessment of the translational capacity of the transgene as function of time and cell number.
在基因水平上对疾病的分子定义以及重组DNA技术的进展表明,许多疾病都可以通过不携带导致疾病的缺陷元件的基因来纠正。在这种疗法用于治疗慢性病之前,必须回答许多问题。这些问题可分为安全性和有效性两类。将皮肤细胞成分或皮肤替代物(定义为具有细胞类型和真皮结构以发育成功能正常皮肤的皮肤)移植到无胸腺啮齿动物身上的经验相当丰富,并且被视为一个可以回答这些问题的系统。本文回顾了这些问题,并展示了我们对体内和体外皮肤替代物中基因修饰细胞的早期分析。实验数据表明,编织尼龙基质(容纳成纤维细胞产生的胶原蛋白)和无活性真皮都可用于将基因修饰的人类成纤维细胞从实验室转运到体内环境。基因修饰的成纤维细胞不会从转运载体迁移到周围组织。在这些转运载体中,大量(约70%)基因修饰的成纤维细胞至少存活6周,这支持了这种一般方法具有临床实用性。还得出结论,皮肤替代物系统可用于在体外生成基因修饰的皮肤,这种皮肤有能力在体内发育成功能正常的皮肤。此外,随着基因修饰的角质形成细胞分化,转基因的产量增加,这支持了角质形成细胞作为治疗性基因转运载体具有真正潜力的概念。这项工作表明,在将这项技术应用于临床之前,含有基因修饰皮肤细胞的系统移植可用于通过实验确定基因治疗在皮肤方面的许多方面。例子包括确定基因转导和表达对基因修饰皮肤以及远处皮肤的结构和功能的影响,以及评估转基因作为时间和细胞数量函数的转化能力。